3D Printing of Drug Delivery Systems
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 1216
Special Issue Editor
Interests: poorly soluble drugs; solid dispersions; amorphous formulation; nanocrystals; experimental design; 3D printing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Disease treatment is still largely based on a so-called one-size-fits-all approach, in which similar drug doses are prescribed to a large number of patients without taking into account the interindividual differences between them. In addition to tailoring therapy to the anatomical and physiological characteristics of individual patients, the acceptability of therapy to individual patients in terms of the dosing frequency, the number of drugs in therapy, and the appearance, size, colour, taste and textural properties of the dosage form is becoming increasingly important. The application of 3D printing technology offers practitioners the ability to produce small batches of drug delivery systems customized to individual patient characteristics and preferences, and provide tailored drug release. Since the FDA approved the first 3D-printed drug Spritam®, interest in the pharmaceutical application of 3D printing has been expanding in both academia and industry, leading to a number of publications and the appearance of the first 3D printers specifically designed for pharmaceutical purposes. However, further intensive research is required, and should focus in particular on the material properties and parameters of the printing process; these should be controlled in order to obtain a consistent product. A less stringent regulatory approach compared to conventional pharmaceutical production is certainly needed for the implementation of 3D printing at the point-of-care, where the benefits of this technology can be best exploited.
This Special Issue welcomes both original and review articles that address recent advances and future directions in the 3D printing of drug delivery systems.
Dr. Djordje Medarevic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- additive manufacturing
- 3D printing
- personalized drug delivery systems
- tailored drug release
